Pfizer Inc
The xAI-SpaceX merger, Palantir earnings, China’s frowning horses and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. I did my workout studio’s Hyrox-themed class yesterday, which not only left me sore but also with a better understanding of what all the hype in the fitness business is about. S&P 500 futures ticked higher this morning. The stock […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More
S&P 500 futures climb after index starts February trading on a winning note: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) on Jan. 28, 2026 in New York City. Spencer Platt | Getty Images Futures linked to the S&P 500 rose on Tuesday after U.S. equities posted a strong start to the new trading month. S&P 500 futures added 0.1%, while Nasdaq 100 futures […]
Read More
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
Check out the companies making headlines before the bell: Palantir — The stock jumped 11% following the AI-powered software provider’s fourth-quarter earnings beat . Palantir reported adjusted earnings of 25 cents per share, versus the 23 cents expected from analysts polled by LSEG. Revenue was $1.41 billion, topping the $1.33 billion consensus estimate. Merck — […]
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026. Oscar Molina | CNBC Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December. […]
Read More
The metal sell-off, Disney earnings, the ‘Melania’ movie and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Good morning. America’s favorite groundhog, Punxsutawney Phil, saw his shadow this morning, meaning we’re in for six more weeks of winter. After the recent string of cold temperatures, I can’t say I’m surprised. Stock futures are sliding this morning. The three major […]
Read More
Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data
The stock market is well-positioned to bounce next week if the heavyweight companies set to report earnings deliver strong numbers, CNBC’s Jim Cramer said Friday. That’s because the market ended the week on a subdued note, the “Mad Money” host said, after the S&P 500 finished in the red for three straight days. The busy […]
Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase […]
Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]
Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]
Read More